|Recombinant Human LILRB3 Protein (Catalog#11978-H08H)|
|0.2 μm filtered solution in PBS with 5% trehalose|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human LILRB3 (rh LILRB3; Catalog#11978-H08H; NP_006855.2; Met 1-Glu 443). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.|
No cross-reactivity with Human cell lysate (293 cell line) in ELISA.
ELISA: 0.5-1 μg/mL
This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human LILRB3. The detection limit for Human LILRB3 is approximately 0.0195 ng/well.
ELISA(Cap): 0.5-4 µg/ml
This antibody will detect Human LILRB3 in ELISA pair set (Catalog: # SEK11978). In a sandwich ELISA, it can be used as capture antibody.
Leukocyte immunoglobulin-like receptor subfamily B member 3, also known as Leukocyte immunoglobulin-like receptor 3, Immunoglobulin-like transcript 5, Monocyte inhibitory receptor HL9, CD85 antigen-like family member A, CD85a and LILRB3, is a single-pass type I membrane protein which belongs to the leukocyte receptor cluster (LRC) present on 19q13.4. LILRB3 / CD85a contains four Ig-like C2-type (immunoglobulin-like) domains. LILRB3 / CD85a contains three copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases. LILRB3 / CD85a is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found.